Leukemia Clinical Trials 2026: AML, CLL, ALL and New Treatments

The four leukemias do not belong in the same sentence — not biologically, not clinically, and not from a research standpoint. CML became the template for all of targeted oncology when imatinib converted a uniformly fatal disease into a chronic condition with near-normal life expectancy in 2001. AML is still fighting that battle in a disease with a far more complex mutational landscape; venetoclax plus azacitidine changed the standard of care for unfit patients in 2020, but most patients still relapse within two years. The ALL story sits somewhere in between: pediatric protocols now cure 85–90% of children, while adult ALL outcomes remain substantially worse — and the E1910 blinatumomab trial in MRD-positive Philadelphia chromosome-negative ALL is the most important development in that disease in a decade. In 2026, getting into the right leukemia trial starts with one prerequisite that most patients and many oncologists underestimate: comprehensive molecular profiling. Without knowing your FLT3, IDH1/2, KMT2A, NPM1, TP53, or IGHV status, you cannot identify the trials most likely to help you.

Acute Myeloid Leukemia (AML): Targeted Therapy in a Complex Disease

AML is the most common acute leukemia in adults, with median age at diagnosis of 68. For decades, the standard treatment was intensive induction chemotherapy — "7+3" (cytarabine plus an anthracycline) — which most older patients cannot tolerate and which cures fewer than 30% of patients overall. The venetoclax plus azacitidine combination, FDA-approved in 2020 based on the VIALE-A trial, changed the standard of care for patients unfit for intensive chemotherapy: complete remission in approximately 65% of newly diagnosed patients versus 22% with azacitidine alone. Median overall survival improved from 9.6 to 14.7 months. Those numbers mark genuine progress. They also make clear that most patients still relapse — and the central research agenda in 2026 is resistance mechanisms and how to overcome them.

The molecular complexity of AML is why this disease has resisted the clean therapeutic narrative that CML created. Roughly 30% of AML carries FLT3 mutations; 30% carries NPM1 mutations; 20% carries IDH1 or IDH2 mutations; 5–10% carries KMT2A rearrangements; and approximately 10–15% carries TP53 mutations — the subset with the worst prognosis across all modern regimens. These genetic categories are not mutually exclusive, and each has a different optimal trial strategy in 2026.

Menin Inhibitors: A Genuine Molecular Breakthrough for KMT2A and NPM1

Menin inhibitors are the most conceptually interesting AML development of the past three years. KMT2A rearrangements (formerly called MLL rearrangements) create fusion oncoproteins that require the MEN1 protein as a co-factor to maintain the aberrant transcriptional program driving leukemia. Disrupting the menin-KMT2A interaction forces differentiation and cell death. Revumenib (Revuforj, Syndax) was FDA-approved in November 2023 for adults and pediatric patients aged 1 year and older with relapsed or refractory AML with KMT2A rearrangement — the first approved targeted therapy for this subset. The AUGMENT-101 Phase 1/2 trial demonstrated a 30% complete remission or complete remission with partial hematologic recovery rate in heavily pretreated patients who had exhausted prior standard therapies.

The NPM1-mutant angle is equally important because NPM1 mutations are the most common single mutation in AML — approximately 30% of cases. NPM1 mutations create a menin-KMT2A dependency through an indirect mechanism: mutant NPM1 protein drives aberrant HOX gene expression, which requires KMT2A occupancy that is itself menin-dependent. Ziftomenib (KaryoPharm) exploits this vulnerability. KOMET-007 Phase 1 data showed a 50% complete remission rate in relapsed/refractory NPM1-mutant AML. The KOMET-008 Phase 3 trial is now enrolling NPM1-mutant patients in the frontline setting, combining ziftomenib with venetoclax plus azacitidine. If that Phase 3 signal holds, it would represent the first genotype-specific modification to the frontline backbone — potentially meaningful for the largest molecular subset of AML.

Menin inhibitors are also being tested in KMT2A-rearranged pediatric ALL, where this genetic subtype carries particularly poor prognosis in infants. The GRAFITI trial is evaluating revumenib plus venetoclax plus azacitidine in newly diagnosed KMT2A-rearranged AML, and post-transplant maintenance trials are assessing whether continued menin inhibition after allogeneic stem cell transplant reduces relapse rates.

FLT3-Mutant AML: Inhibitor Combinations Push into Triplet Territory

FLT3 mutations — FLT3-ITD (internal tandem duplication) and FLT3-TKD (tyrosine kinase domain) — occur together in approximately 30% of AML patients. The RATIFY trial established midostaurin plus standard induction as the first FLT3-targeted frontline regimen in 2017, improving OS (HR 0.78). Gilteritinib displaced salvage chemotherapy as second-line standard for FLT3-mutant relapsed/refractory AML in the ADMIRAL trial (median OS 9.3 vs. 5.6 months, HR 0.64). The 2026 research direction is triplet intensification: the QuAVA trial evaluates quizartinib — a more FLT3-ITD selective inhibitor than midostaurin — combined with venetoclax plus azacitidine for newly diagnosed FLT3-ITD-positive patients ineligible for intensive chemotherapy. LACEWING evaluated gilteritinib plus azacitidine in older and unfit FLT3-positive AML, and that combination's tolerability profile is now informing second-generation trial design. The question being answered in 2026 is whether triplet regimens (FLT3 inhibitor + venetoclax + hypomethylating agent) can extend the duration of remission beyond what doublets achieve, without unacceptable cumulative toxicity.

Venetoclax Resistance: The Dominant Research Problem

Understanding venetoclax resistance mechanisms is now arguably the most important question in AML research. BCL-2 mutations at G101V eliminate the binding pocket that venetoclax occupies; upregulation of MCL-1 and BCL-XL shifts apoptotic dependency to pathways that venetoclax doesn't inhibit. Each resistance mechanism corresponds to a different override strategy. Magrolimab (anti-CD47 antibody, Gilead) blocks the "don't eat me" phagocytic signal on leukemic cells. The ENHANCE Phase 3 trial evaluated magrolimab plus azacitidine specifically for TP53-mutant AML — the subset that responds poorly to every current regimen — and top-line results are being closely watched as the first potentially meaningful therapy for this population. Navitoclax adds BCL-XL and BCL-2 co-inhibition to overcome BCL-XL-mediated resistance. IDH1-mutant relapsed disease has dedicated trials with ivosidenib plus venetoclax. The common thread: knowing your resistance mechanism requires repeat molecular profiling at relapse, not just at diagnosis.

Chronic Lymphocytic Leukemia (CLL): Managing Success and What Comes After

CLL has been more completely transformed by targeted therapy than almost any other hematologic malignancy. Ibrutinib, approved in 2014, was the first BTK inhibitor to demonstrate superiority over chemoimmunotherapy in frontline CLL — a result that was genuinely surprising to the field at the time. Subsequent approvals of acalabrutinib and zanubrutinib offered improved selectivity and tolerability over first-generation ibrutinib. Venetoclax plus obinutuzumab, established in CLL14, demonstrated that fixed-duration therapy could achieve undetectable MRD in approximately 75% of patients with durable remissions. Five-year survival rates exceed 80% in many CLL subgroups. The research agenda has shifted from "can we treat CLL?" to two more refined questions: can fixed-duration doublet or triplet combinations achieve treatment-free remission that rivals continuous BTK inhibition, and what do we do with the growing population of patients who have exhausted both BTK inhibitors and venetoclax?

Pirtobrutinib and the Non-Covalent BTK Strategy

Covalent BTK inhibitors bind irreversibly at the C481 cysteine residue. The C481S resistance mutation eliminates this binding site and is the dominant mechanism of acquired resistance to ibrutinib, acalabrutinib, and zanubrutinib. Pirtobrutinib (Jaypirca, Lilly) is a non-covalent, reversible BTK inhibitor that retains full inhibitory activity against C481S-mutant BTK. FDA approval in January 2023 was based on BRUIN Phase 1/2 data showing a 73.3% ORR in post-BTKi CLL patients. The BRUIN-CLL-321 Phase 3 trial confirmed superiority over investigator's choice regimen (idelalisib plus rituximab or bendamustine plus rituximab) in patients who had received both a covalent BTK inhibitor and venetoclax — the population previously left with the fewest options. PFS hazard ratio was approximately 0.54, a clinically meaningful improvement. BRUIN-CLL-322 is now evaluating pirtobrutinib in earlier-line settings, and combinations with venetoclax are being explored in Phase 1/2 trials.

Fixed-Duration Combinations and MRD-Driven Treatment Decisions

The CLL14 trial result — fixed-duration venetoclax plus obinutuzumab producing undetectable MRD in ~75% of patients, with 4-year PFS of 74% — fundamentally changed what fixed-duration CLL therapy could achieve. The question now is whether adding a BTK inhibitor to a venetoclax plus anti-CD20 backbone produces even deeper and more durable MRD negativity. SEQUOIA evaluates zanubrutinib plus venetoclax as a BTKi-venetoclax doublet. ACE-CLL-311 (AMPLIFY) tests acalabrutinib plus venetoclax plus obinutuzumab as a triplet. CAPTIVATE examined ibrutinib plus venetoclax with MRD-guided treatment duration — patients who achieved undetectable MRD after 12 cycles could stop treatment, with promising durability at follow-up. These trials collectively address whether deeper response translates to longer treatment-free survival in a disease where indefinite BTK inhibitor therapy was becoming the clinical default.

IGHV mutation status remains the single most prognostically important biomarker in CLL. Unmutated IGHV is associated with more aggressive disease, earlier relapse, and historically worse outcomes with chemoimmunotherapy — but outcomes with BTK inhibitors are more comparable between IGHV-mutated and unmutated patients. Trial eligibility for CLL protocols almost universally requires IGHV status and 17p deletion/TP53 mutation status to be documented.

Acute Lymphoblastic Leukemia (ALL): Closing the Adult-Pediatric Gap

Adult ALL presents a persistent problem in hematologic oncology: pediatric protocols cure 85–90% of children, yet overall survival in adults — particularly those over 60 — remains substantially worse. Part of the explanation is biological: adult ALL has a higher frequency of Philadelphia chromosome-positive disease (Ph+ALL), BCR-ABL1-like (Ph-like) ALL with diverse activated kinase fusions, and TP53 alterations — each associated with inferior outcomes. But part of the gap is also due to adults being unable to tolerate pediatric chemotherapy intensities. The E1910 trial addressed a specific, tractable problem: MRD-positive disease during first remission in Philadelphia chromosome-negative ALL.

Blinatumomab Moves into Frontline Consolidation

Blinatumomab (Blincyto) is a bispecific T cell engager — it simultaneously binds CD19 on leukemic B cells and CD3 on T cells, bringing cytotoxic T cells into direct contact with leukemic blasts without requiring antigen presentation. It had been approved for relapsed/refractory B-ALL and MRD-positive disease after prior therapy. The E1910 trial (ECOG-ACRIN) asked a more ambitious question: does adding blinatumomab to consolidation chemotherapy in newly diagnosed Ph-negative ALL patients who achieved first complete remission but retained measurable residual disease improve outcomes? The answer was yes — blinatumomab added to consolidation significantly improved overall survival versus consolidation chemotherapy alone in MRD+ patients. This is now driving revision of ALL treatment algorithms to incorporate blinatumomab into consolidation phases for MRD+ Ph-negative disease.

Ph+ALL has its own trajectory. The combination of ponatinib (third-generation TKI, active against T315I) plus blinatumomab in newly diagnosed Ph+ALL achieved complete MRD negativity in 86% of patients in a Phase 2 trial — with no patients undergoing stem cell transplant in first complete remission in that protocol. If durable, this could shift Ph+ALL from a disease requiring transplant in virtually all patients toward chemotherapy-free or reduced-intensity pathways. This is where 2026 Phase 3 trials are heading.

CAR-T and the CD19-Loss Problem

Tisagenlecleucel (Kymriah) was the first CAR-T approved for B-ALL (in patients up to age 25) and remains the only CAR-T specifically approved for adult B-ALL. Complete remission rates of 60–90% have been reported in highly pretreated patients — impressive for a population with no other meaningful options. The durability problem is well-characterized: approximately 30–50% of patients who achieve remission after CD19-directed CAR-T relapse with CD19-negative disease, an antigen escape mechanism where leukemic cells survive by downregulating or losing the target antigen. Dual-target CAR-T constructs co-targeting CD19 and CD22 are in trials specifically to address this: if leukemic cells lose CD19, CD22-directed cytotoxicity is maintained, and vice versa. CD22-directed CAR-T as monotherapy is enrolling in trials for patients who relapsed with CD19 loss after prior CD19 CAR-T — a population with essentially no other cellular therapy options. Axicabtagene ciloleucel, currently approved only for adult large B cell lymphoma, is under evaluation for adult B-ALL in 2026 Phase 2 trials based on preliminary activity signals.

How to Access Leukemia Trials: Practical Considerations

Molecular profiling before searching

Most modern leukemia trials gate eligibility on specific genetic alterations. AML trials require documented FLT3, IDH1/IDH2, KMT2A, NPM1, CEBPA, and TP53 status. CLL trials require IGHV mutation status and 17p deletion / TP53 mutation status. ALL trials require Philadelphia chromosome status and BCR-ABL1 quantification by PCR. If comprehensive next-generation sequencing has not been performed at diagnosis or at relapse, you cannot systematically search for trials relevant to your disease. This is the prerequisite — before opening ClinicalTrials.gov, before calling a trial site, before asking your oncologist about options. Molecular profiling at relapse is distinct from profiling at diagnosis; resistance mutations can emerge during treatment and these new alterations may open or close different trial pathways.

Where leukemia trials are concentrated

Leukemia trials — particularly Phase 2 and Phase 3 AML and ALL trials — are concentrated at NCI-designated Cancer Centers, large academic hematology programs, and ECOG-ACRIN / Alliance for Clinical Trials in Oncology cooperative group institutions. Industry-sponsored Phase 1 trials for novel agents are often run at a smaller number of highly specialized sites initially. Community oncology practices typically do not run leukemia trials independently but may have referral relationships with academic centers. If you are being treated at a community practice, explicitly ask your oncologist whether a consultation at an academic hematology center would identify trial options — the molecular complexity of modern leukemia makes a second opinion at a specialized center reasonable for most newly diagnosed or relapsed patients, regardless of where you ultimately receive treatment.

Timing is uniquely critical in AML

AML moves faster than most solid tumors. Frontline trial enrollment windows open early in the disease course — often requiring enrollment before first treatment or during the first cycle. Salvage trials at first relapse have distinct eligibility windows from second or third relapse. Some trials require washout periods from prior therapies. Patients with rapidly proliferating AML may not have weeks to travel to distant sites for evaluation. The practical recommendation — which experienced hematologists consistently give — is to discuss trial options proactively while still in first remission, before relapse occurs. Identify the trials your disease molecular profile would qualify for, understand the nearest enrolling sites, and document the contact information. That preparation substantially increases the probability of successfully enrolling if and when first remission fails.

Frequently Asked Questions